{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T04:07:54Z","timestamp":1747454874758,"version":"3.40.5"},"reference-count":36,"publisher":"Sociedade Brasileira de Cardiologia","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,19]]},"DOI":"10.36660\/abc.20200128","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T20:47:24Z","timestamp":1614372444000},"page":"285-294","source":"Crossref","is-referenced-by-count":1,"title":["Associa\u00e7\u00e3o entre Terapia com Estatinas e Menor Incid\u00eancia de Hiperglicemia em Pacientes Internados com S\u00edndromes Coronarianas Agudas"],"prefix":"10.36660","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4639-1003","authenticated-orcid":false,"given":"Remo Holanda de Mendon\u00e7a","family":"Furtado","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7995-8304","authenticated-orcid":false,"given":"Paulo Rizzo","family":"Genestreti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Talia F.","family":"Dal\u00e7\u00f3quio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciano Moreira","family":"Baracioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe Galego","family":"Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Franci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto R. C. V.","family":"Giraldez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando R.","family":"Menezes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aline Gehlen","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviane Moreira","family":"Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesar A. C.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Alberto Kenji","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rocio","family":"Salsoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6171-1269","authenticated-orcid":false,"given":"Lucas Colombo","family":"Godoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 C.","family":"Nicolau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22636","reference":[{"issue":"8934","key":"key20210226154717_B1","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","unstructured":". Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344(8934):1383-9.","journal-title":"Lancet"},{"issue":"14","key":"key20210226154717_B2","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","unstructured":". LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC,  et al. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005; 352(14):1425\u201335.","journal-title":"N Engl J Med"},{"issue":"21","key":"key20210226154717_B3","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","unstructured":". Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ,  et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359(21):2195=-207.","journal-title":"N Engl J Med"},{"issue":"21","key":"key20210226154717_B4","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa1600176","article-title":"HOPE-3 Investigators. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease","volume":"374","author":"Yusuf","year":"2016","unstructured":". Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L,  et al. HOPE-3 Investigators. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med. 2016 May 26; 374(21):2021-31.","journal-title":"N Engl J Med"},{"issue":"25","key":"key20210226154717_B5","first-page":"e1082","article-title":"2018AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol","volume":"139","author":"Grundy","year":"2019","unstructured":". Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS,  et al. 2018AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol. Circulation. 2019; 139(25):e1082-e1143.","journal-title":"Circulation"},{"issue":"15","key":"key20210226154717_B6","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","unstructured":". Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R,  et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350(15):1495-504.","journal-title":"N Engl J Med"},{"issue":"13","key":"key20210226154717_B7","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial","volume":"285","author":"Schwartz","year":"2001","unstructured":". Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D,  et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285(13):1711-8.","journal-title":"JAMA"},{"issue":"14","key":"key20210226154717_B8","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jacc.2010.04.023","article-title":"Evidence of pre-procedural statin therapy a meta-analysis of randomized trials","volume":"56","author":"Winchester","year":"2010","unstructured":". Winchester DE, Wen X, Xie L, Bavry AA. Evidence of pre-procedural statin therapy a meta-analysis of randomized trials. J Am Coll Cardiol.2010;56(14):1099-109.","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"key20210226154717_B9","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1001\/jama.2018.2444","article-title":"Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial","volume":"319","author":"Berwanger","year":"2018","unstructured":". Berwanger O, Santucci EV, Silva PG, Jesu\u00edno IA, Damiani LP, Barbosa LM,  et al. Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial. JAMA. 2018; 319(13):1331-40.","journal-title":"JAMA"},{"issue":"9716","key":"key20210226154717_B10","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","unstructured":". Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, Craen AJ,  et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375(9716): 735\u201342.","journal-title":"Lancet"},{"issue":"9841","key":"key20210226154717_B11","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(12)61190-8","article-title":"Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial","volume":"380","author":"Ridker","year":"2012","unstructured":". Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012; 380(9841):565\u201371.","journal-title":"Lancet"},{"key":"key20210226154717_B12","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f2610","article-title":"Risk of incident diabetes among patients treated with statins: population based study","volume":"346","author":"Carter","year":"2013","unstructured":". Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: population based study. BMJ. 2013; 346: f2610.","journal-title":"BMJ"},{"issue":"2","key":"key20210226154717_B13","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00125-015-3802-6","article-title":"Effect of atorvastatin on glycaemia progression in patients with diabetes: an analysis from the Collaborative Atorvastatin in Diabetes Trial (CARDS)","volume":"59","author":"Livingstone","year":"2016","unstructured":". Livingstone SJ, Looker HC, Akbar T, Betteridge DJ, Durrington PN, Hitman GA,  et al. Effect of atorvastatin on glycaemia progression in patients with diabetes: an analysis from the Collaborative Atorvastatin in Diabetes Trial (CARDS). Diabetologia .2016; 59(2):299-306.","journal-title":"Diabetologia"},{"issue":"12","key":"key20210226154717_B14","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1007\/s00125-014-3374-x","article-title":"Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis","volume":"57","author":"Erqou","year":"2014","unstructured":". Erqou S, Lee CC, Adler AI. Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis. Diabetologia. 2014; 57(12):2444-52.","journal-title":"Diabetologia"},{"issue":"6","key":"key20210226154717_B15","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.metabol.2014.02.014","article-title":"Daskalopoulou SS. Statin treatment and new-onset diabetes: a review of proposed mechanisms","volume":"63","author":"Brault","year":"2014","unstructured":". Brault M, Ray J, Gomez YH, Mantzoros CS, Daskalopoulou SS. Statin treatment and new-onset diabetes: a review of proposed mechanisms. Metabolism. 2014; 63(6):735-45.","journal-title":"Metabolism"},{"issue":"11","key":"key20210226154717_B16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142902","article-title":"Simvastatin Impairs Insulin Secretion by Multiple Mechanisms in MIN6 Cells","volume":"10","author":"Yaluri","year":"2015","unstructured":". Yaluri N, Modi S, L\u00f3pez Rodr\u00edguez M, Stan\u010d\u00e1kov\u00e1 A, Kuusisto J, Kokkola T,  et al. Simvastatin Impairs Insulin Secretion by Multiple Mechanisms in MIN6 Cells. PLoS One. 2015; 10(11):e0142902.","journal-title":"PLoS One"},{"issue":"1","key":"key20210226154717_B17","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2337\/db19-0178","article-title":"Atorvastatin Targets the Islet Mevalonate Pathway to Dysregulate mTOR Signaling and Reduce \u03b2-Cell Functional Mass","volume":"69","author":"Shen","year":"2020","unstructured":". Shen L, Gu Y, Qiu Y, Cheng T, Nie A, Cui C,  et al. Atorvastatin Targets the Islet Mevalonate Pathway to Dysregulate mTOR Signaling and Reduce \u03b2-Cell Functional Mass. Diabetes. 2020; 69(1):48-59.","journal-title":"Diabetes"},{"key":"key20210226154717_B18","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2016.00324","article-title":"Early Effects of Treatment Low-Dose Atorvastatin on Markers of Insulin Resistance and Inflammation in Patients with Myocardial Infarction","volume":"7","author":"Gruzdeva","year":"2016","unstructured":". Gruzdeva O, Uchasova E, Dyleva Y, Akbasheva O, Karetnikova V, Barbarash O. Early Effects of Treatment Low-Dose Atorvastatin on Markers of Insulin Resistance and Inflammation in Patients with Myocardial Infarction. Front Pharmacol. 2016; 7:324.","journal-title":"Front Pharmacol"},{"issue":"1","key":"key20210226154717_B19","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1001\/jama.286.1.64","article-title":"Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation\/CRP evaluation (PRINCE): a randomized trial and cohort study","volume":"286","author":"Albert","year":"2001","unstructured":". Albert MA, Danielson E, Rifai N, Ridker PM; PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation\/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286(1):64-70.","journal-title":"JAMA"},{"issue":"1","key":"key20210226154717_B20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker","year":"2005","unstructured":". Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH,  et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352(1):20-8.","journal-title":"N Engl J Med"},{"issue":"2","key":"key20210226154717_B21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)","volume":"39","author":"Ibanez","year":"2018","unstructured":". Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H,  et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39(2):119-77.","journal-title":"Eur Heart J"},{"issue":"7578","key":"key20210226154717_B22","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.38985.646481.55","article-title":"Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE)","volume":"333","author":"Fox","year":"2006","unstructured":". Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Werf FV,  et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ. 2006; 333(7578):1091.","journal-title":"BMJ"},{"issue":"3","key":"key20210226154717_B23","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jacc.2016.10.060","article-title":"Comparison of Propensity Score Methods and Covariate Adjustment: Evaluation in 4 Cardiovascular Studies","volume":"69","author":"Elze","year":"2017","unstructured":". Elze MC, Gregson J, Baber U, Williamsom E, Sartori S, Mehran R,  et al. Comparison of Propensity Score Methods and Covariate Adjustment: Evaluation in 4 Cardiovascular Studies. J Am Coll Cardiol. 2017; 69(3):345-57.","journal-title":"J Am Coll Cardiol"},{"issue":"9206","key":"key20210226154717_B24","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0140-6736(99)08415-9","article-title":"Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview","volume":"355","author":"Capes","year":"2000","unstructured":". Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000; 355(9206):773\u20138.","journal-title":"Lancet"},{"key":"key20210226154717_B25","article-title":"Association of statin use and stress-induced hyperglycemia in patients with acute ST-elevation myocardial infarction","volume":"5","author":"Yan","year":"2016","unstructured":". Yan C, Qin M, Juan YS, Tao LY, Dong GM, Zechun Z,  et al. Association of statin use and stress-induced hyperglycemia in patients with acute ST-elevation myocardial infarction. JRSM Cardiovasc Dis. 2016; 5:2048004016639442.","journal-title":"JRSM Cardiovasc Dis"},{"issue":"1","key":"key20210226154717_B26","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-52111-x","article-title":"Statin Short-term Inhibition of Insulin Sensitivity and Secretion During Acute Phase of ST-Elevation Myocardial Infarction","volume":"9","author":"Sposito","year":"2019","unstructured":". Sposito AC, Carvalho LSF, Moura FA, Staffico AM, Cintra RM, Nadruz W,  et al. Statin Short-term Inhibition of Insulin Sensitivity and Secretion During Acute Phase of ST-Elevation Myocardial Infarction. Sci Rep. 2019; 9(1):16401.","journal-title":"Sci Rep"},{"issue":"1","key":"key20210226154717_B27","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jacc.2013.04.105","article-title":"Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome)","volume":"63","author":"Leoncini","year":"2014","unstructured":". Leoncini M, Toso A, Maioli M, Tropeano F, Villani S, Bellandi F. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome). J Am Coll Cardiol. 2014; 63(1):71-9.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"key20210226154717_B28","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jacc.2013.09.017","article-title":"Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease","volume":"63","author":"Han","year":"2014","unstructured":". Han Y, Zhu G, Han L, Hou F, Huang W, Liu H,  et al. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. J Am Coll Cardiol. 2014; 63(1):62-70.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"key20210226154717_B29","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.jcin.2014.06.023","article-title":"Relationship Between Inflammation and Benefits of Early High-Dose Rosuvastatin on Contrast-Induced Nephropathy inPatients With Acute Coronary Syndrome: The Pathophysiological Link in the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy on Contrast-Induced Nephropathy and Myocardial Damage in Patients With Acute Coronary Syndrome Undergoing Coronary Intervention)","volume":"7","author":"Toso","year":"2014","unstructured":". Toso A, Leoncini M, Maioli M, Tropeano F, Vicenzo E, Villani S,  et al. Relationship Between Inflammation and Benefits of Early High-Dose Rosuvastatin on Contrast-Induced Nephropathy inPatients With Acute Coronary Syndrome: The Pathophysiological Link in the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy on Contrast-Induced Nephropathy and Myocardial Damage in Patients With Acute Coronary Syndrome Undergoing Coronary Intervention). JACC Cardiovasc Interv. 2014; 7(12):1421-9.","journal-title":"JACC Cardiovasc Interv"},{"issue":"11","key":"key20210226154717_B30","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/jamacardio.2018.3408","article-title":"Timing of Loading Dose of Atorvastatin in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes: Insights From the SECURE-PCI Randomized Clinical Trial","volume":"3","author":"Lopes","year":"2018","unstructured":". Lopes RD, Silva PG, Jesu\u00edno IA, Santucci EV, Barbosa LM, Damiani LP,  et al. Timing of Loading Dose of Atorvastatin in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes: Insights From the SECURE-PCI Randomized Clinical Trial. JAMA Cardiol. 2018; 3(11):1113-8.","journal-title":"JAMA Cardiol"},{"issue":"11","key":"key20210226154717_B31","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehi884","article-title":"Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study","volume":"279","author":"Goyal","year":"2006","unstructured":". Goyal A, Mahaffey KW, Garg J, Nicolau JC, Hochman JS, Weaver WD,  et al. Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study. Eur Heart J 2006; 279(11):1289\u201397.","journal-title":"Eur Heart J"},{"issue":"2","key":"key20210226154717_B32","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.yexcr.2019.04.039","article-title":"Glucose impairs angiogenesis and promotes ventricular remodeling following myocardial infarction via upregulation of microRNA-17","volume":"381","author":"Yana","year":"2019","unstructured":". Yana M, Chena K, Suna R, Lin K, Qian X, Yuan M,  et al. Glucose impairs angiogenesis and promotes ventricular remodeling following myocardial infarction via upregulation of microRNA-17. Exp Cell Res. 2019; 381(2):191\u2013200.","journal-title":"Exp Cell Res"},{"issue":"7","key":"key20210226154717_B33","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/eurheartj\/ehi199","article-title":"Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity","volume":"26","author":"Malmberg","year":"2005","unstructured":". Malmberg K, Ryd\u00e9n L, Wedel H, Birkeland K, Bootsma A, Dickstein K,  et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J. 2005; 26(7):650-61.","journal-title":"Eur Heart J"},{"issue":"13","key":"key20210226154717_B34","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1056\/NEJMoa0810625","article-title":"Intensive versus conventional glucose control in critically ill patients","volume":"360","author":"NICE-SUGAR","year":"2009","unstructured":". NICE-SUGAR Study Investigators, Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V,  et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360(13):1283\u201397.","journal-title":"N Engl J Med"},{"issue":"1","key":"key20210226154717_B35","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.diabres.2009.10.008","article-title":"Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis","volume":"87","author":"Baker","year":"2010","unstructured":". Baker WL, Talati R, White CM, Coleman CI. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2010; 87(1):98-107.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"key20210226154717_B36","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-018-0799-4","article-title":"Effect of statins on fasting glucose in non diabetic individuals: nationwide population based health examination in Korea","volume":"17","author":"Kim","year":"2018","unstructured":". Kim J, Lee HS, Lee KY. Effect of statins on fasting glucose in non diabetic individuals: nationwide population based health examination in Korea. Cardiovasc Diabetol. 2018; 17(1):155.","journal-title":"Cardiovasc Diabetol"}],"container-title":["Arquivos Brasileiros de Cardiologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/abccardiol.org\/article\/associacao-entre-terapia-com-estatinas-e-menor-incidencia-de-hiperglicemia-em-pacientes-internados-com-sindromes-coronarianas-agudas\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T13:03:44Z","timestamp":1747400624000},"score":1,"resource":{"primary":{"URL":"http:\/\/abccardiol.org\/article\/associacao-entre-terapia-com-estatinas-e-menor-incidencia-de-hiperglicemia-em-pacientes-internados-com-sindromes-coronarianas-agudas\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2,19]]}},"alternative-id":["10.36660\/abc.20200128"],"URL":"https:\/\/doi.org\/10.36660\/abc.20200128","relation":{},"ISSN":["0066-782X","1678-4170"],"issn-type":[{"type":"print","value":"0066-782X"},{"type":"electronic","value":"1678-4170"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}